CALPOL Six Plus 250mg/5ml Oral Suspension *
General Sale: Non-prescription

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 22 August 2021

File name

ie-leaflet-calpol 6 plus suspension - 2082_1629652726.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 22 August 2021

File name

ie-spc-v10 calpol 6 plus suspension - 2082_1629652626.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category:Supply through general sale

Updated on 12 December 2019

File name

ie-spc-v9 calpol 6 plus suspension - 2004_1576140736.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Supply through general sale

Updated on 02 December 2019

File name

ie-spc-v8 calpol 6 plus suspension 1935_1575268014.pdf

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category:Supply through general sale

Updated on 02 December 2019

File name

LEAFLET Calpol SixPlus Suspension_1575267969.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 05 April 2019

File name

ie-pil-Calpol Six Plus Suspension - 1807_1554454019.pdf

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 05 April 2019

File name

ie-spc-v7-calpol 6 plus suspension bv-1807_1554454099.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category:Supply through general sale

Updated on 10 December 2018

File name

ie-leaflet -1837_1544442950.pdf

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 10 December 2018

File name

ie-spc V8 Calpol Six Plus Oral Suspension 1837_1544442925.pdf

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category:Supply through general sale

Updated on 28 June 2018

File name

LN513801-PIL CALPOL 6PLUS 60ML IEv7_11.pdf

Reasons for updating

  • Improved presentation of PIL

Updated on 29 July 2015

File name

PIL_8770_828.pdf

Reasons for updating

  • New PIL for new product

Updated on 29 July 2015

Reasons for updating

  • New SPC for new product

Legal category:Supply through general sale

Updated on 29 July 2015

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties

Legal category:Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 4.4 - the following warning has been added:

Serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens - Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), have been reported very rarely in patients receiving paracetamol. Patients should be informed about the signs of serious skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.

Section 4.6 has been updated as follows:

There are no adequate and well-controlled clinical studies in pregnant or breastfeeding women. Epidemiological studies indicate that paracetamol, when taken as directed, does not adversely affect the pregnant mother or fetus.

 

Pregnancy

When given to the mother in labeled doses, paracetamol crosses the placenta into fetal circulation as early as 30 minutes after ingestion and is effectively metabolized by fetal sulfate conjugation. When taken as directed, paracetamol

does not adversely affect the pregnant mother or fetus

 

Breastfeeding

Paracetamol is excreted in breast milk in low concentrations (0.1% to 1.85% of the ingested maternal dose). Maternal ingestion of paracetamol in labeled doses does not present a risk to the nursing infant.



Section 4.8 & 4.9 have been updated with new information - please see revised SPC for details. Section 4.8 has also been updated with Adverse events reporting information

Section 5.1 - the following paragraph has been added

ATC Code: N02BE01 – Other analgesics and antipyretics

Paracetamol is a centrally acting, non-opiate, non-salicylate analgesic. Paracetamol is a clinically proven analgesic/antipyretic, and it is thought to produce analgesia by elevation of the pain threshold and antipyresis through action on the hypothalamic heat-regulating centre.  Single-dose studies (12.5 mg/kg) of paracetamol in febrile children showed an onset of fever reduction within 15 to 30 minutes. 

SNAS 1339

Updated on 29 July 2015

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 19 January 2012

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Supply through general sale

Free text change information supplied by the pharmaceutical company

Implementation of change(s) requested by the National Competent Authority following the assessment of the paracetamol pediatric dosing schedule (section 4.2) with subsequent changes to section 4.4 warnings and precautions.

Updated on 17 January 2012

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to dosage and administration

Updated on 14 February 2011

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category:Supply through general sale

Free text change information supplied by the pharmaceutical company

Renewal updates.

Update to Section 2 - list of excipients
Update to Section 4.4. - excipient warnings

Renewal date updated
Revision of text date updated

Updated on 11 February 2011

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to storage instructions

Updated on 17 December 2010

Reasons for updating

  • Change due to user-testing of patient information

Updated on 25 August 2008

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category:Supply through general sale

Free text change information supplied by the pharmaceutical company

Change in MAH from Pfizer Consumer Healthcare, Pottery Road, Dun Laoghaire to McNeil Healthcare Ireland Limited, Airton Road, Tallaght, Dublin 24.

Updated on 19 May 2008

Reasons for updating

  • Change to marketing authorisation holder

Updated on 28 August 2007

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Supply through general sale

Free text change information supplied by the pharmaceutical company

Section 4.4 updated to add: Patients with  rare hereditary problems of fructose intolerance should not take this medicine.

Updated on 14 November 2005

Reasons for updating

  • Change to packaging

Updated on 10 September 2004

Reasons for updating

  • New PIL for medicines.ie

Updated on 18 June 2003

Reasons for updating

  • New SPC for medicines.ie

Legal category:Supply through general sale